All stock reports

CHEMBOND evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-03T23:40:11.621595+00:00

Metrics

latest_annual_period
2026-03-31
revenue
2500740000.0
net_income
128907000.0
operating_cash_flow
162592000.0
free_cash_flow
-48056000.0
total_assets
2194202000.0
total_liabilities
524791000.0
total_equity
1669412000.0
cash
379726000.0
total_debt
41570000.0
revenue_growth
0.24420186923327614
earnings_growth
-0.2660057850863208
net_margin
0.05154754192758943
roe
0.0772170081441849
debt_to_equity
0.024900983100636633
cash_conversion
1.261312419030774
free_cash_flow_margin
-0.019216711853291425
trailing_pe
Not supplied
forward_pe
Not supplied
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Price Dislocation

Research only. Direction: LONG.

Flags large price dislocations for research without asserting unsupported fundamental quality

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Continued price deterioration or adverse fundamental evidence
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-8bd0876def4240f31601a687f3a34fdcae677e2af918ee92b729594b0c1be6c0
Policy
stock-decisions-v1
Evidence bundle hash
8ab440de155f1b209ad6004b375a0af555e33bd1d417a680419e308797dd6dca
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 6bfc9756501c094ec1133d51f9069d16e5e863a0be51f916783e4e882deb8278
  • daily-price: aeb4492038119078bee6d4e481ae886f2c275d78acc90484a014a0b68673c36d
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: REPAIRED. The trailing 5-session price return was -7.28%. The trailing 20-session price return was 5.95%. The trailing 60-session price return was -3.34%. The trailing 250-session price return was 2.76%. Average cached traded value over twenty sessions was INR 6,952,860.

Risks

The closing price was -21.34% below its highest close in the available trailing year. The cached financial metric free cash flow margin is -0.019216711853291425. Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Follow Up

The cached financial metric latest annual period is 2026-03-31. The cached financial metric revenue growth is 0.24420186923327614. The cached financial metric net margin is 0.05154754192758943. The cached financial metric roe is 0.0772170081441849. The cached financial metric debt to equity is 0.024900983100636633. The cached financial metric cash conversion is 1.261312419030774.

Cached observations and evidence limits